PRONOUNCE Trial: Cardiovascular Outcomes in Prostate Cancer - Susan Slovin

(Length of Conversation: 19 min)

Alicia Morgans, MD, MPH and Susan Slovin, MD, PhD, discuss the PRONOUNCE trial, which looks at cardiovascular outcomes in patients with prostate cancer.  Dr. Slovin highlights the importance of considering cardiovascular disease as it is the second most common cause of death in men with prostate cancer. 

Literature in the past 15-20 years on the use a GNRH agonists has linked to increasing cardiovascular mortality and morbidity in men.  The increase in risk is particularly apparent within the first year of treatment, therefore men with a history of cardiovascular disease are most likely to be at even greater risk if they go on these drugs.  This among other factors has led to a need for multidisciplinary care coordination. 

The PRONOUNCE trial aims to assess three points: whether a GNRH agonists or antagonist can worsen preexisting cardiovascular problems.  It is the first to prospectively assess GNRH agonists or antagonist risk factors on cardiovascular biomarkers and the first study to prospectively assess hormonal therapy on the immune system. The prospective data from this study will ultimately help guide physicians to development guidelines for the prospective management of patients clinically rather than expert opinion, retrospective analysis or meta analysis.   Dr. Slovin and Dr. Morgans also discuss the physiology differences between antagonist and agonist and the potential effects of the immune system.   Listeners will also learn how they can contribute and enroll patients in this important trial.

Biography:

Susan Slovin, MD, PhD, is Attending Physician and Member in the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine, Department of Medicine at Joan and Sanford I Weill Medical College of Cornell University.  A noted immunologist, she has been involving with the Prostate Cancer Foundation in leading an initiative which focuses on the development of novel immunologic approaches for the treatment of prostate cancer. She is a member of several professional associations, including the American Society of Clinical Oncology, American Association of Immunologists, American Association of Investigative Pathology, and American Association of Cancer Researchers, American Urologic Association and Sigma Xi Research Society. 

Alicia Morgans, MD, MPH

Related Content:

A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)

Watch: Navigating the Adverse Effects of ADT: Improving Patient Outcomes - Jehonathan Pinthus and Neal Shore

Watch: Assessment of Cardiovascular Risk with the Use of Androgen Deprivation Therapy for Prostate Cancer - Matthew Roe

The PRONOUNCE Trial for patients with advanced prostate cancer and cardiovascular disease receiving degarelix or leuprolide.